Literature DB >> 6203890

Investigations into the mechanism of action of the antibacterial agent norfloxacin.

G C Crumplin, M Kenwright, T Hirst.   

Abstract

Examination of the mechanism of action of norfloxacin upon susceptible strains of Escherichia coli K12 has shown that the drug exerts a potent bactericidal effect resulting from the inhibition of the A subunit of the essential enzyme DNA gyrase. It is also shown that the use of norfloxacin can reduce the total number of bacteria at the site of an infection as well as having significant effects upon the metabolism of treated cells in the interim period between the loss of viability and cell-lysis. These effects may provide a clue to a previously unsuspected mechanism of providing symptomatic relief which functions in parallel with the elimination of viable pathogenic bacteria.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203890     DOI: 10.1093/jac/13.suppl_b.9

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  43 in total

1.  Accumulation of enoxacin by Escherichia coli and Bacillus subtilis.

Authors:  J Bedard; S Wong; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 2.  The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

Authors:  C S Lewin; I Morrissey; J T Smith
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition.

Authors:  S Vincent; B Glauner; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

5.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

7.  Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.

Authors:  J S Wolfson; D C Hooper; D J Shih; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

8.  In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

Authors:  E Wakabayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus.

Authors:  N H Georgopapadakou; B A Dix; Y R Mauriz
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

10.  Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth.

Authors:  A Forsgren; A Bredberg; A B Pardee; S F Schlossman; T F Tedder
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.